(thirdQuint)Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy.

 This Phase 3, open label safety and efficacy study will be performed at participating sites worldwide.

 The study will enroll ~ 220 boys with nonsense mutation dystrophinopathy who participated in a previous Phase 3 study of ataluren (Protocol # PTC124-GD-020-DMD).

 Patients will receive 10, 10, 20 mg/kg of ataluren TID at morning, midday, and evening for approximately 96 weeks.

 Study assessments will be performed at clinic visits every 12 weeks.

.

 Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy@highlight

The main goal of this Phase 3 extension study is to obtain long term safety of ataluren in boys with nonsense mutation dystrophinopathy as determined by adverse events and laboratory abnormalities.

 The study will also assess changes in physical function, pulmonary function and other important clinical and laboratory measures.

